What neuropathology teaches us about autoimmune encephalitides, autoimmune epilepsies, and encephalomyelitides
Clin Neuropathol. 2023 Mar 31. doi: 10.5414/NP301536. Online ahead of print.ABSTRACTDelineation of the autoimmune encephalitides with antibodies against neural surface antigens (anti-N-Methyl-D-aspartate, anti-leucine-rich glioma-inactivated protein 1, and others), autoimmune-associated epilepsies (Rasmussen encephalitis, paraneoplastic encephalitides, temporal lobe epilepsy with antibodies against glutamic acid decarboxylase), and encephalomyelitides with glial antibodies (neuromyelitis optica spectrum disorder, myelin oligodendrocyte glycoprotein antibody disease) has been a major advance in neurology. But how do these i...
Source: Clinical Neuropathology - March 31, 2023 Category: Pathology Authors: Christian G Bien Jan Bauer Source Type: research
Molecular imaging of gliomas
Clin Neuropathol. 2023 Mar 31. doi: 10.5414/NP301535. Online ahead of print.ABSTRACTMolecular characterization has become a key diagnostic tool for the classification and grading of primary brain tumors. Molecular markers, such as isocitrate dehydrogenase (IDH) mutation status, 1p/19q codeletion, methylation of the O(6)-methylguanine-DNA methyltransferase (MGMT) promoter, or CDKN2A/B homozygous deletion discriminate different tumor entities and grades, and play a crucial role for treatment response and prognosis. In recent years, magnetic resonance imaging (MRI), whose main functions has been to detect a tumor, to provide ...
Source: Clinical Neuropathology - March 31, 2023 Category: Pathology Authors: Marie-Christin Metz Benedikt Wiestler Source Type: research
Update on quality assurance in neuropathology: Summary of the round robin trials on TERT promoter mutation, H3-3A mutation, 1p/19q codeletion, and KIAA1549::BRAF fusion testing in Germany in 2020 and 2021
Clin Neuropathol. 2023 Mar 31. doi: 10.5414/NP301547. Online ahead of print.ABSTRACTWe previously reported on the first neuropathological round robin trials operated together with Quality in Pathology (QuIP) GmbH in 2018 and 2019 in Germany, i.e., the trials on IDH mutational testing and MGMT promoter methylation analysis [1]. For 2020 and 2021, the spectrum of round robin trials has been expanded to cover the most commonly used assays in neuropathological institutions. In addition to IDH mutation and MGMT promoter methylation testing, there is a long tradition for 1p/19q codeletion testing relevant in the context of the d...
Source: Clinical Neuropathology - March 31, 2023 Category: Pathology Authors: Sandra Pohl Lora Dimitrova Maja Grassow-Narlik Korinna J öhrens Till Acker Hildegard Dohmen Jochen Herms Mario Dorostkar Christian Hartmann Martin Hasselblatt Manuela Neumann Guido Reifenberger J örg Felsberg Ulrich Sch üller Saida Zoubaa Julia Lorenz Source Type: research
What neuropathology teaches us about autoimmune encephalitides, autoimmune epilepsies, and encephalomyelitides
Clin Neuropathol. 2023 Mar 31. doi: 10.5414/NP301536. Online ahead of print.ABSTRACTDelineation of the autoimmune encephalitides with antibodies against neural surface antigens (anti-N-Methyl-D-aspartate, anti-leucine-rich glioma-inactivated protein 1, and others), autoimmune-associated epilepsies (Rasmussen encephalitis, paraneoplastic encephalitides, temporal lobe epilepsy with antibodies against glutamic acid decarboxylase), and encephalomyelitides with glial antibodies (neuromyelitis optica spectrum disorder, myelin oligodendrocyte glycoprotein antibody disease) has been a major advance in neurology. But how do these i...
Source: Clinical Neuropathology - March 31, 2023 Category: Pathology Authors: Christian G Bien Jan Bauer Source Type: research
Molecular imaging of gliomas
Clin Neuropathol. 2023 Mar 31. doi: 10.5414/NP301535. Online ahead of print.ABSTRACTMolecular characterization has become a key diagnostic tool for the classification and grading of primary brain tumors. Molecular markers, such as isocitrate dehydrogenase (IDH) mutation status, 1p/19q codeletion, methylation of the O(6)-methylguanine-DNA methyltransferase (MGMT) promoter, or CDKN2A/B homozygous deletion discriminate different tumor entities and grades, and play a crucial role for treatment response and prognosis. In recent years, magnetic resonance imaging (MRI), whose main functions has been to detect a tumor, to provide ...
Source: Clinical Neuropathology - March 31, 2023 Category: Pathology Authors: Marie-Christin Metz Benedikt Wiestler Source Type: research
